United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 11.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,499 shares of the biotechnology company’s stock after buying an additional 2,720 shares during the period. Nisa Investment Advisors LLC’s holdings in United Therapeutics were worth $8,997,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of UTHR. JPMorgan Chase & Co. grew its position in United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after acquiring an additional 50,291 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares in the last quarter. Burney Co. grew its holdings in shares of United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after purchasing an additional 12,705 shares in the last quarter. Bridgewater Associates LP increased its stake in United Therapeutics by 384.3% during the 3rd quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock worth $22,130,000 after buying an additional 49,003 shares during the period. Finally, Glenmede Trust Co. NA lifted its holdings in United Therapeutics by 6.4% during the 3rd quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after buying an additional 4,145 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 224 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the sale, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the transaction, the chief financial officer now directly owns 6,978 shares in the company, valued at $2,442,300. This represents a 52.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 146,848 shares of company stock worth $55,165,099. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 0.2 %

UTHR opened at $371.89 on Friday. The firm has a market cap of $16.60 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 0.94 and a beta of 0.57. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The business’s 50 day moving average is $365.04 and its two-hundred day moving average is $355.24.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the prior year, the firm earned $5.38 EPS. United Therapeutics’s revenue for the quarter was up 22.9% on a year-over-year basis. Equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on UTHR shares. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. HC Wainwright upped their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.